Guardant Health, Inc. $GH Stock Holdings Lessened by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 14.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,275 shares of the company’s stock after selling 10,625 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Guardant Health were worth $11,643,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. HighTower Advisors LLC boosted its position in shares of Guardant Health by 1.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,802 shares of the company’s stock valued at $4,067,000 after purchasing an additional 412 shares during the period. Intech Investment Management LLC increased its stake in Guardant Health by 54.2% in the 3rd quarter. Intech Investment Management LLC now owns 15,138 shares of the company’s stock worth $2,700,000 after purchasing an additional 5,319 shares in the last quarter. Trillium Asset Management LLC acquired a new stake in Guardant Health during the 3rd quarter worth about $2,181,000. Bellwether Advisors LLC acquired a new stake in Guardant Health during the 3rd quarter worth about $1,395,000. Finally, Diversified Trust Co acquired a new stake in Guardant Health during the 3rd quarter worth about $661,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GH has been the subject of a number of analyst reports. Stifel Nicolaus upped their price objective on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, July 31st. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. Guggenheim boosted their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Morgan Stanley boosted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Barclays upped their price target on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.88.

Get Our Latest Stock Report on GH

Guardant Health Stock Performance

Shares of GH stock opened at $143.28 on Wednesday. The stock’s 50 day simple moving average is $167.94 and its 200 day simple moving average is $133.33. Guardant Health, Inc. has a twelve month low of $74.55 and a twelve month high of $191.05. The company has a market capitalization of $19.38 billion, a price-to-earnings ratio of -38.93 and a beta of 1.67.

Guardant Health (NASDAQ:GH – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to the consensus estimate of $350.72 million. During the same period in the previous year, the company earned ($0.74) EPS. The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. On average, analysts forecast that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.

Insider Activity

In other news, Director Alex Azar, II sold 826 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director directly owned 825 shares in the company, valued at approximately $144,375. The trade was a 50.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 37,500 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the completion of the sale, the chief executive officer owned 37,500 shares of the company’s stock, valued at $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 53,224 shares of company stock worth $9,116,546. 5.60% of the stock is owned by company insiders.

About Guardant Health

(Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.